Workers face intense challenges as radiation remains lethal and tasks must be performed in short shifts.

Japanese drugmaker Daiichi Sankyo’s (TYO:4568) Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

The damaged Unit 1 reactor, back, and the exhaust stack shared by the Unit 1 and 2 reactors are seen at the Fukushima Daiichi nuclear power plant, operated by Tokyo Electric Power Company Holdings ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

Samsung’s Project Moohan XR headset might have been on show at MWC 2025, but Samsung didn’t actually give us any information on what to expect from the device. However a new report from The ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

AstraZeneca and Daiichi Sankyo also recently won the FDA’s approval for another ADC they are working on together. Datroway, which also carries a topoisomerase I inhibitor but instead targets the TROP2 ...

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1. ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Daiichi Sankyo’s antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is ...